血液DNA甲基化标志物与1型糖尿病糖尿病肾病进展相关
该研究在芬兰1型糖尿病队列中对403例正常白蛋白尿者和372例严重白蛋白尿者进行全表观基因组关联研究,随访糖尿病肾病进展。共识别11个与进展相关的甲基化位点,其中早期进展位点独立于基线eGFR,晚期进展位点与eGFR强相关;cg17944885与终末期肾病强关联。纳入甲基化标志物可改善早期进展风险识别。
要点
- 11个甲基化位点与1型糖尿病糖尿病肾病进展相关。
- cg01730944等早期进展位点独立于基线eGFR。
- cg17944885与终末期肾病强关联,获既往研究支持。
核心结论
- 研究检测到11个与糖尿病肾病进展相关的甲基化位点,首次识别出可预测1型糖尿病早期糖尿病肾病进展的甲基化变化。
研究设计与样本
- 基于芬兰1型糖尿病糖尿病肾病研究队列的基线血样DNA甲基化数据进行全表观基因组关联研究。
- 纳入403例正常白蛋白尿者(早期进展组)和372例严重白蛋白尿者(晚期进展组)。
- 在另外两个1型糖尿病队列及已发表的糖尿病和一般人群EWAS汇总统计中进行复制。
主要发现
- 识别11个与糖尿病肾病进展相关的甲基化位点(p<9.4 × 10-8)。
- cg01730944(靠近足细胞特异性基因CDKN1C)及其他3个与早期进展相关的CpG独立于基线eGFR。
- 晚期进展相关CpG与eGFR强相关;先导ESKD风险位点cg17944885(chr19p13.2,p=2.6 × 10-17)获既往研究支持。
- cg14999724甲基化与PRG3和PRG2相关,cg12272104与BSG、FSTL3和PALM相关;UK Biobank数据显示这些蛋白与严重肾脏终点相关。
- 包含甲基化标志物和临床风险因素的生存模型显著改善早期糖尿病肾病进展风险识别。
临床怎么用
- 在临床风险因素基础上纳入DNA甲基化标志物,可能改善1型糖尿病早期糖尿病肾病进展的风险分层。
局限性
- 仍需未来研究确立用于糖尿病肾病进展的预后DNA甲基化标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: DNA methylation has been shown to be associated with kidney function and diabetic kidney disease (DKD), but prospective studies are scarce. Therefore, we conducted epigenome-wide association studies (EWASs) on early- and late-stage DKD progression using DNA methylation data obtained by analysing baseline blood samples from participants in the Finnish Diabetic Nephropathy Study type 1 diabetes cohort. METHODS: We included 403 individuals with normal AER (early-stage progression group) and 372 individuals with severe albuminuria (late-stage progression group), and followed up DKD progression, defined as a decrease in eGFR to <60 ml/min per 1.73 m2 in the early-stage progression group, and end-stage kidney disease (ESKD) in the late-stage group. Replication was conducted in two type 1 diabetes cohorts in addition to publicly available EWAS summary statistics from diabetes and general population cohorts. Significant loci were further characterised by integration with genetic and proteomic data. RESULTS: We identified 11 methylation sites associated with DKD progression (p<9.4 × 10-8). Methylation at cg01730944 near the podocyte-specific gene CDKN1C and three other CpGs associated with early-stage DKD progression were independent of baseline eGFR, whereas late-stage progression CpGs were strongly associated with eGFR. The identified lead ESKD risk locus cg17944885 (chr19p13.2, p=2.6 × 10-17) and several novel methylation sites associated with late-stage DKD progression were supported by the results of previous studies. Proteomic analysis of cis proteins identified potential target genes for two CpGs: cg14999724 methylation was associated with PRG3 and PRG2, and cg12272104 was associated with BSG, FSTL3 and PALM. Furthermore, UK Biobank data show associations between these proteins and severe kidney endpoints. Finally, survival models that included methylation markers in addition to clinical risk factors significantly improved the identification of individuals at risk of early-stage DKD progression. CONCLUSIONS/INTERPRETATION: The current study detected 11 loci associated with DKD progression, identifying methylation changes predictive of early-stage DKD progression in type 1 diabetes for the first time. Future research is needed to establish prognostic DNA methylation markers for DKD progression.
引用
- Syreeni A, Dahlström EH, Smyth LJ, et al. Blood DNA methylation markers are associated with diabetic kidney disease progression in type 1 diabetes. Diabetologia. 2026. PMID: 41569424. doi:10.1007/s00125-025-06661-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。